We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Stronger Together: Eliminating Racial Healthcare Inequities

By Jen A. Miller (AACC)
Posted on 07 Jul 2023
Health equity remains an important emphasis throughout healthcare, including in laboratory medicine. More...
But recognizing disparities in healthcare—and developing solutions to make sure that everyone has equal access to cutting-edge medicine—will only be realized if laboratorians play an active role.

The session, Stronger Together: Eliminating Racial Healthcare Inequities by Mitigating Systemic Racism, by Drs. Christina Pierre, Esa Davis, and Octavia Peck Palmer will focus on racism as a key driver of health inequities, specifically how structural racism influences social determinants of health that lead to poorer health and well-being in racial and ethnic minorities.

Pierre began her laboratory medicine career in her home country of Trinidad, where she identified screening gaps based on socioeconomic status. “It’s not so much that I chose this topic to present, it’s that it is a primary, core focus of the work that I do every day,” she said.

Social unrest in 2020 pushed issues of health equity to the forefront, and Pierre wants to keep pushing forward toward change. “The current social climate tells us why we need to keep paying attention to underprivileged populations, regardless of what identity that person has that makes them underserved or disadvantaged,” Pierre said.

The session will explore how laboratorians can equip themselves to deal with this complex health dilemma and provide foundational and up-to-date information to empower participants to identify the health impacts of structural racism. The speakers also will offer tools to mitigate these impacts and achieve health equity through laboratory medicine and clinical practice workflows.

The session also will present new recommendations from AACC and the National Kidney Foundation on improving equity in kidney disease. This is an important topic in health equity because early detection of kidney disease can lead to interventions that significantly slow down disease progress, Pierre said.

However, most early kidney disease detection happens in a primary care setting, and people who don’t have a primary care physician may be missed, she noted. “How do we ensure that we are optimizing healthcare across the board and not just for a particular group?”

For example, clinical laboratorians can play a role in examining how to use electronic health records to increase the uptake of screening or support physicians on utilizing kidney screening tests, she added.

Panelist Astor Davis is a member of the U.S. Preventive Services Task Force, and will speak to guidance aimed at mitigating systemic racism in guideline development and clinical preventative services. She will discuss how screening guidelines can be adopted to offer a national, unified approach to ensuring preventative testing and care for all. Peck Palmer will also be discussing how to develop a health equity program within both a clinical laboratory and medical institution.

Pierre believes that the panel will be of interest to medical professions across industries, including those working in patient care, clinical laboratory scientists, laboratory directors, and point-of-care coordinators. “My hope is that we can keep a central focus on health equity and make it a part of what we do in our day to day lives,” she said. “People often view health equity as a special mindset, topic, or area of study. But if we have identified groups of patients who have poorer outcomes, then we’re never going to achieve progress if we don’t address the contributing factors to those groups experiencing poorer health outcomes.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.